We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Back to Healio DENVER — Primary generalized tonic-clonic ...
A phase 3 study assessing the use pregabalin as adjunctive therapy for epilepsy patients 5 to 65 years of age with primary generalized tonic-clonic (PGTC) seizures did not meet its primary endpoint to ...
The FDA also approved Vimpat Injection for use in pediatric patients 4 years of age and older. The Food and Drug Administration (FDA) has approved Vimpat ® (lacosamide; UCB) as adjunctive therapy in ...
LONDON--(BUSINESS WIRE)-- LivaNova PLC (LIVN), a market-leading medical technology company, today announced that 24-month data on generalized tonic-clonic (GTC) seizures in people with drug-resistant ...
--UCB, a global pharmaceutical company, today announced that the U.S. Food and Drug Administration has approved VIMPAT ® CV as adjunctive therapy in the treatment of primary generalized tonic-clonic ...
ATLANTA, June 24, 2024 /PRNewswire/ -- UCB, a global biopharmaceutical company, today announced that Epilepsia published findings from a comprehensive scoping review examining the efficacy of FINTEPLA ...
TOKYO, May 13, 2024 - (JCN Newswire) - - Eisai Co., Ltd. announced today that it has received approval in China for the additional indication of its in-house discovered antiepileptic drug (AED) ...
Early Infantile Epileptic Encephalopathy (EIEE) or Ohtahara syndrome is a severe and congenital seizure disorder that affects neonates within the first three months of life, and often within the first ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback